Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Notable: Comparative Study of Regional Nerve Blocks in Primary Cleft Palate Repair Primary endpoint(s) modified
- Notable: Core Competencies in General Intensive Care Ultrasound (GenIUS): a Delphi Study Enrolling by invitation only
- Notable: Multi-Strain Probiotic Supplementation (Hexbio®) in Malaysian · Drug-Resistant Epilepsy (ProbE) Primary endpoint(s) modified
- Notable: SBU-RESET · RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors Primary endpoint(s) modified
- Notable: Motor Control Exercises With and Without Pressure Biofeedback in Recurrent Low Back Pain (MCE) Primary endpoint(s) modified
- Notable: Short-Term Safety and Performance of a Wound Dressing Evaluation Primary endpoint(s) modified
- Notable: Imagery Rescripting as a Treatment for Early Psychosis Primary endpoint(s) modified
- Notable: Virtual Reality Application and Progressive Relaxation Exercise Primary endpoint(s) modified
- Notable: FLASH Pilot Phase 1 Safety Study Primary endpoint(s) modified
- Notable: Mobile Health Education to Enhance Self-management and Reduce Dose Delays for Breast Cancer Patients Receiving First-Time Chemotherapy: Randomized Controlled Trial Results posted: Nov 16, 2026
- Notable: Elderly Patients, Does Goal-directed Fluid Management Using the Carotid Corrected Flow Time (CC-FT) Index, Compared to Routine Fluid Management, Affect the Occurrence of Post-induction Hypotension? Primary endpoint(s) modified
- Notable: Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength Primary endpoint(s) modified
- Notable: Virtual Reality-based Rehabilitation for Traumatic Hand and Wrist Injuries Primary endpoint(s) modified
- Notable: Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy Device Enrollment increased: 60 → 90 participants
- Notable: Citicoline Eye Drops 2% on Visual Field Preservation · Open Angle Glaucoma Primary and study completion dates pushed to Jul 1, 2029
- Notable: Zasocitinib in Children and Teenagers With Plaque Psoriasis Primary and study completion pushed from Jan 24, 2033 to Jul 3, 2034
- Notable: TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone · Recurrent Glioblastoma Primary completion pushed from Jul 2027 to Jul 2028
- Notable: Patients With Primary Vitreoretinal Lymphoma Primary and study completion pushed from Dec 2026 to Dec 2029
- Notable: Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules · Advanced or Unresectable Alveolar Soft Part Sarcoma Primary completion pushed from Nov 2027 to Dec 2028
- Notable: OPT101 · Type 1 Diabetes Mellitus Primary completion pushed from May 31, 2026 to May 31, 2027
- Notable: Intrathecally Administered Gene Therapy AMT-162 · SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) Primary completion pushed from Sep 30, 2026 to Dec 30, 2030
- Notable: Relacorilant in Combination With Different Treatment Regimens · Gynecological Cancers Primary completion pushed from Aug 2026 to Dec 2027
- Notable: NHWD-870 HCl in Adults and · Advanced NUT Cancer Primary completion pushed from Jun 30, 2025 to Mar 30, 2027
- Notable: Ablation of Arteries · Type 2 Diabetes Mellitus and Its Comorbidities Primary completion pushed from Jan 2025 to Jun 2027
- Notable: Arterial Ablation · Type 2 Diabetes Mellitus and Its Comorbidities Primary completion pushed from Jan 2025 to May 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates